Insider Trades123 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 1,600 | $235.18 | $25.9B | -4.92% | +37.30% | $376.3K | -13.41% | 10b5-1 | Stalk |
| Jul 22, 2026 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 102 | $206.81 | $25.9B | -4.92% | +37.30% | $21.1K | +0.31% | — | Stalk |
| Jun 4, 2026 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 16,294 | $162.11 | $25.9B | -4.92% | +37.30% | $2.6M | +0.00% | 10b5-1 | Stalk |
| Jun 1, 2026 | Sell | DGX | J. E. Davis | CEO and President | 10,000 | $194.14 | $25.9B | -4.92% | +37.30% | $1.9M | -7.02% | 10b5-1 | Stalk |
| Apr 20, 2026 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 108 | $194.70 | $25.9B | -4.92% | +37.30% | $21.0K | +0.32% | — | Stalk |
| Mar 4, 2026 | Buy | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 2,223 | $204.86 | $25.9B | -4.92% | +37.30% | $455.4K | +1.03% | — | Stalk |
| Mar 4, 2026 | Buy | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 8,008 | $204.86 | $25.9B | -4.92% | +37.30% | $1.6M | +14.79% | — | Stalk |
| Mar 4, 2026 | Buy | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 8,828 | $204.86 | $25.9B | -4.92% | +37.30% | $1.8M | +13.77% | — | Stalk |
| Mar 4, 2026 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 11,364 | $205.20 | $25.9B | -4.92% | +37.30% | $2.3M | +0.00% | 10b5-1 | Stalk |
| Mar 4, 2026 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 14,464 | $205.22 | $25.9B | -4.92% | +37.30% | $3.0M | +0.00% | 10b5-1 | Stalk |
| Mar 4, 2026 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 21,667 | $204.86 | $25.9B | -4.92% | +37.30% | $4.4M | +9.15% | — | Stalk |
| Mar 4, 2026 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 22,728 | $205.19 | $25.9B | -4.92% | +37.30% | $4.7M | +0.00% | 10b5-1 | Stalk |
| Mar 4, 2026 | Buy | DGX | J. E. Davis | CEO and President | 78,066 | $204.86 | $25.9B | -4.92% | +37.30% | $16.0M | +8.82% | — | Stalk |
| Mar 2, 2026 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 88 | $204.86 | $25.9B | -4.92% | +37.30% | $18.0K | -0.25% | — | Stalk |
| Mar 2, 2026 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 188 | $204.86 | $25.9B | -4.92% | +37.30% | $38.5K | -2.16% | — | Stalk |
| Mar 2, 2026 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 205 | $204.86 | $25.9B | -4.92% | +37.30% | $42.0K | -2.03% | — | Stalk |
| Mar 2, 2026 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 640 | $206.70 | $25.9B | -4.92% | +37.30% | $132.3K | -2.04% | 10b5-1 | Stalk |
| Mar 2, 2026 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 814 | $206.71 | $25.9B | -4.92% | +37.30% | $168.3K | -1.06% | 10b5-1 | Stalk |
| Mar 2, 2026 | Sell | DGX | Sam Samad | Executive Vice President & CFO | 869 | $204.86 | $25.9B | -4.92% | +37.30% | $178.0K | -3.11% | — | Stalk |
| Mar 2, 2026 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 1,280 | $206.28 | $25.9B | -4.92% | +37.30% | $264.0K | -0.94% | 10b5-1 | Stalk |
| Mar 2, 2026 | Sell | DGX | J. E. Davis | CEO and President | 12,968 | $210.77 | $25.9B | -4.92% | +37.30% | $2.7M | -5.04% | 10b5-1 | Stalk |
| Feb 18, 2026 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 182 | $208.37 | $25.9B | -4.92% | +37.30% | $37.9K | -0.26% | — | Stalk |
| Feb 18, 2026 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 435 | $208.41 | $25.9B | -4.92% | +37.30% | $90.7K | -1.72% | — | Stalk |
| Feb 18, 2026 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 511 | $208.48 | $25.9B | -4.92% | +37.30% | $106.5K | -1.93% | — | Stalk |
| Feb 18, 2026 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 1,495 | $206.10 | $25.9B | -4.92% | +37.30% | $308.1K | -2.48% | — | Stalk |
| Feb 18, 2026 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 1,759 | $206.14 | $25.9B | -4.92% | +37.30% | $362.6K | -1.37% | — | Stalk |
| Feb 18, 2026 | Sell | DGX | Sam Samad | Executive Vice President & CFO | 1,934 | $207.49 | $25.9B | -4.92% | +37.30% | $401.3K | -1.72% | — | Stalk |
| Feb 18, 2026 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 2,594 | $206.30 | $25.9B | -4.92% | +37.30% | $535.1K | -1.15% | — | Stalk |
| Feb 18, 2026 | Sell | DGX | J. E. Davis | CEO and President | 6,184 | $208.16 | $25.9B | -4.92% | +37.30% | $1.3M | -1.80% | — | Stalk |
| Feb 13, 2026 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 52,330 | $159.16 | $25.9B | -4.92% | +37.30% | $8.3M | +0.00% | 10b5-1 | Stalk |
| Jan 28, 2026 | Buy | DGX | Patrick Plewman | SVP for Diagnostic Services | 11,372 | $162.99 | $25.9B | -4.92% | +37.30% | $1.9M | +0.09% | 10b5-1 | Stalk |
| Nov 25, 2025 | Sell | DGX | J. E. Davis | CEO and President | 110,186 | $144.01 | $25.9B | -4.92% | +37.30% | $15.9M | +0.00% | 10b5-1 | Stalk |
| Nov 18, 2025 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 15,892 | $165.90 | $25.9B | -4.92% | +37.30% | $2.6M | +0.00% | 10b5-1 | Stalk |
| Nov 5, 2025 | Sell | DGX | J. E. Davis | CEO and President | 7,143 | $175.57 | $25.9B | -4.92% | +37.30% | $1.3M | -5.60% | — | Stalk |
| Oct 21, 2025 | Buy | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 15 | $189.08 | $25.9B | -4.92% | +37.30% | $2.8K | +0.18% | — | Stalk |
| Oct 21, 2025 | Buy | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 15 | $189.08 | $25.9B | -4.92% | +37.30% | $2.8K | +0.20% | — | Stalk |
| Oct 21, 2025 | Buy | DGX | Patrick Plewman | SVP for Diagnostic Services | 46 | $189.08 | $25.9B | -4.92% | +37.30% | $8.7K | +0.30% | — | Stalk |
| Oct 21, 2025 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 68 | $189.08 | $25.9B | -4.92% | +37.30% | $12.9K | +0.26% | — | Stalk |
| Sep 26, 2025 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 454 | $145.85 | $25.9B | -4.92% | +37.30% | $66.2K | +0.00% | 10b5-1 | Stalk |
| Sep 23, 2025 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 56,926 | $145.35 | $25.9B | -4.92% | +37.30% | $8.3M | +0.00% | 10b5-1 | Stalk |
| Aug 21, 2025 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 1,975 | $185.00 | $25.9B | -4.92% | +37.30% | $365.4K | -11.45% | 10b5-1 | Stalk |
| Aug 19, 2025 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 9,064 | $147.59 | $25.9B | -4.92% | +37.30% | $1.3M | +0.00% | 10b5-1 | Stalk |
| Aug 15, 2025 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 1,975 | $180.00 | $25.9B | -4.92% | +37.30% | $355.5K | -10.28% | 10b5-1 | Stalk |
| Aug 13, 2025 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 123 | $175.91 | $25.9B | -4.92% | +37.30% | $21.6K | -1.45% | — | Stalk |
| Aug 6, 2025 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 9,095 | $140.41 | $25.9B | -4.92% | +37.30% | $1.3M | -2.94% | 10b5-1 | Stalk |
| Jul 30, 2025 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 18,748 | $139.20 | $25.9B | -4.92% | +37.30% | $2.6M | -3.59% | 10b5-1 | Stalk |
| Jul 16, 2025 | Sell | DGX | Sam Samad | Executive Vice President & CFO | 850 | $169.01 | $25.9B | -4.92% | +37.30% | $143.7K | -3.21% | — | Stalk |
| May 12, 2025 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 1,748 | $175.51 | $25.9B | -4.92% | +37.30% | $306.8K | -9.92% | 10b5-1 | Stalk |
| Apr 2, 2025 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 2,555 | $170.00 | $25.9B | -4.92% | +37.30% | $434.4K | -19.46% | 10b5-1 | Stalk |
| Apr 2, 2025 | Sell | DGX | J. E. Davis | CEO and President | 39,191 | $168.46 | $25.9B | -4.92% | +37.30% | $6.6M | -1.81% | 10b5-1 | Stalk |
| Mar 26, 2025 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 162 | $166.71 | $25.9B | -4.92% | +37.30% | $27.0K | -0.77% | — | Stalk |
| Mar 26, 2025 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 256 | $166.71 | $25.9B | -4.92% | +37.30% | $42.7K | -2.70% | — | Stalk |
| Mar 17, 2025 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 4,643 | $170.00 | $25.9B | -4.92% | +37.30% | $789.3K | -10.86% | 10b5-1 | Stalk |
| Mar 5, 2025 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 5,370 | $174.13 | $25.9B | -4.92% | +37.30% | $935.1K | -7.31% | 10b5-1 | Stalk |
| Mar 4, 2025 | Buy | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 7,140 | $173.74 | $25.9B | -4.92% | +37.30% | $1.2M | +20.22% | — | Stalk |
| Mar 4, 2025 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 21,568 | $173.74 | $25.9B | -4.92% | +37.30% | $3.7M | +11.43% | — | Stalk |
| Mar 3, 2025 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 4,270 | $173.74 | $25.9B | -4.92% | +37.30% | $741.9K | -0.82% | — | Stalk |
| Mar 3, 2025 | Buy | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 7,305 | $173.74 | $25.9B | -4.92% | +37.30% | $1.3M | +4.21% | — | Stalk |
| Mar 3, 2025 | Buy | DGX | Patrick Plewman | SVP for Diagnostic Services | 8,060 | $173.74 | $25.9B | -4.92% | +37.30% | $1.4M | +5.57% | — | Stalk |
| Mar 3, 2025 | Buy | DGX | Michael E Prevoznik | SVP & General Counsel | 13,369 | $173.83 | $25.9B | -4.92% | +37.30% | $2.3M | +2.29% | 10b5-1 | Stalk |
| Mar 3, 2025 | Buy | DGX | Catherine T. Doherty | EVP, Regional Businesses | 16,500 | $173.83 | $25.9B | -4.92% | +37.30% | $2.9M | +1.50% | 10b5-1 | Stalk |
| Mar 3, 2025 | Buy | DGX | J. E. Davis | CEO and President | 95,235 | $173.74 | $25.9B | -4.92% | +37.30% | $16.5M | +6.04% | — | Stalk |
| Feb 26, 2025 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 88 | $171.75 | $25.9B | -4.92% | +37.30% | $15.1K | -0.25% | — | Stalk |
| Feb 26, 2025 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 214 | $171.75 | $25.9B | -4.92% | +37.30% | $36.8K | -3.45% | — | Stalk |
| Feb 26, 2025 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 229 | $171.75 | $25.9B | -4.92% | +37.30% | $39.3K | -1.27% | — | Stalk |
| Feb 26, 2025 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 233 | $171.75 | $25.9B | -4.92% | +37.30% | $40.0K | -1.98% | — | Stalk |
| Feb 26, 2025 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 814 | $172.31 | $25.9B | -4.92% | +37.30% | $140.3K | -1.03% | 10b5-1 | Stalk |
| Feb 26, 2025 | Sell | DGX | Sam Samad | Executive Vice President & CFO | 869 | $171.75 | $25.9B | -4.92% | +37.30% | $149.3K | -4.13% | — | Stalk |
| Feb 26, 2025 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 1,279 | $172.30 | $25.9B | -4.92% | +37.30% | $220.4K | -0.91% | 10b5-1 | Stalk |
| Feb 26, 2025 | Sell | DGX | J. E. Davis | CEO and President | 2,966 | $171.75 | $25.9B | -4.92% | +37.30% | $509.4K | -2.10% | — | Stalk |
| Feb 19, 2025 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 99 | $169.71 | $25.9B | -4.92% | +37.30% | $16.8K | -0.28% | — | Stalk |
| Feb 19, 2025 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 242 | $169.71 | $25.9B | -4.92% | +37.30% | $41.1K | -3.76% | — | Stalk |
| Feb 19, 2025 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 287 | $169.71 | $25.9B | -4.92% | +37.30% | $48.7K | -2.38% | — | Stalk |
| Feb 19, 2025 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 320 | $169.71 | $25.9B | -4.92% | +37.30% | $54.3K | -1.74% | — | Stalk |
| Feb 19, 2025 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 978 | $170.50 | $25.9B | -4.92% | +37.30% | $166.7K | -1.20% | 10b5-1 | Stalk |
| Feb 19, 2025 | Sell | DGX | Sam Samad | Executive Vice President & CFO | 1,031 | $169.71 | $25.9B | -4.92% | +37.30% | $175.0K | -4.67% | — | Stalk |
| Feb 19, 2025 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 1,434 | $170.51 | $25.9B | -4.92% | +37.30% | $244.5K | -1.00% | 10b5-1 | Stalk |
| Feb 19, 2025 | Sell | DGX | J. E. Davis | CEO and President | 2,936 | $169.71 | $25.9B | -4.92% | +37.30% | $498.3K | -2.04% | — | Stalk |
| Feb 5, 2025 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 403 | $164.30 | $25.9B | -4.92% | +37.30% | $66.2K | -8.02% | — | Stalk |
| Nov 29, 2024 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 70,292 | $124.85 | $25.9B | -4.92% | +37.30% | $8.8M | +0.00% | 10b5-1 | Stalk |
| Nov 27, 2024 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 66,206 | $133.28 | $25.9B | -4.92% | +37.30% | $8.8M | +0.00% | 10b5-1 | Stalk |
| Nov 6, 2024 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 37,510 | $111.35 | $25.9B | -4.92% | +37.30% | $4.2M | +0.00% | 10b5-1 | Stalk |
| Oct 28, 2024 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 1,775 | $156.92 | $25.9B | -4.92% | +37.30% | $278.5K | -15.42% | — | Stalk |
| Sep 24, 2024 | Sell | DGX | Mark A Gardner | SVP of Molecular Gen & Oncol | 120 | $155.70 | $25.9B | -4.92% | +37.30% | $18.7K | -2.50% | — | Stalk |
| Aug 29, 2024 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 65,102 | $125.38 | $25.9B | -4.92% | +37.30% | $8.2M | +0.00% | — | Stalk |
| Aug 28, 2024 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 1,990 | $153.26 | $25.9B | -4.92% | +37.30% | $305.0K | -14.80% | — | Stalk |
| Aug 14, 2024 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 74 | $149.46 | $25.9B | -4.92% | +37.30% | $11.1K | -0.55% | — | Stalk |
| Jul 24, 2024 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 420 | $143.08 | $25.9B | -4.92% | +37.30% | $60.1K | -7.72% | — | Stalk |
| Jul 16, 2024 | Sell | DGX | Sam Samad | Executive Vice President & CFO | 3,910 | $142.65 | $25.9B | -4.92% | +37.30% | $557.8K | -18.31% | — | Stalk |
| Apr 29, 2024 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 1,760 | $140.00 | $25.9B | -4.92% | +37.30% | $246.4K | -11.58% | 10b5-1 | Stalk |
| Apr 22, 2024 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 24 | $126.25 | $25.9B | -4.92% | +37.30% | $3.0K | +0.11% | — | Stalk |
| Apr 22, 2024 | Buy | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 45 | $126.25 | $25.9B | -4.92% | +37.30% | $5.7K | +0.30% | — | Stalk |
| Apr 22, 2024 | Buy | DGX | Patrick Plewman | SVP for Diagnostic Services | 69 | $126.25 | $25.9B | -4.92% | +37.30% | $8.7K | +0.43% | — | Stalk |
| Mar 26, 2024 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 114 | $128.11 | $25.9B | -4.92% | +37.30% | $14.6K | -0.71% | — | Stalk |
| Mar 26, 2024 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 170 | $128.11 | $25.9B | -4.92% | +37.30% | $21.8K | -3.03% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 109 | $126.36 | $25.9B | -4.92% | +37.30% | $13.8K | -0.16% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | Mark E Delaney | SVP & Chief Commercial Officer | 225 | $126.36 | $25.9B | -4.92% | +37.30% | $28.4K | -3.86% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | Mark A Gardner | SVP of Molecular Gen & Oncol | 262 | $126.36 | $25.9B | -4.92% | +37.30% | $33.1K | -5.18% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 273 | $126.36 | $25.9B | -4.92% | +37.30% | $34.5K | -0.89% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 333 | $126.36 | $25.9B | -4.92% | +37.30% | $42.1K | -1.02% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | Sam Samad | Executive Vice President & CFO | 656 | $126.36 | $25.9B | -4.92% | +37.30% | $82.9K | -2.98% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | J. E. Davis | CEO and President | 5,020 | $126.36 | $25.9B | -4.92% | +37.30% | $634.3K | -1.94% | — | Stalk |
| Feb 28, 2024 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 6,472 | $125.94 | $25.9B | -4.92% | +37.30% | $815.1K | -4.84% | 10b5-1 | Stalk |
| Feb 28, 2024 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 7,945 | $126.44 | $25.9B | -4.92% | +37.30% | $1.0M | -2.68% | 10b5-1 | Stalk |
| Feb 23, 2024 | Buy | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 2,320 | $125.02 | $25.9B | -4.92% | +37.30% | $290.0K | +1.52% | 16b | Stalk |
| Feb 23, 2024 | Buy | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 2,658 | $125.02 | $25.9B | -4.92% | +37.30% | $332.3K | +4.73% | 16b | Stalk |
| Feb 23, 2024 | Buy | DGX | Patrick Plewman | SVP for Diagnostic Services | 3,257 | $125.02 | $25.9B | -4.92% | +37.30% | $407.2K | +4.72% | 16b | Stalk |
| Feb 23, 2024 | Buy | DGX | Michael E Prevoznik | SVP & General Counsel | 10,394 | $125.02 | $25.9B | -4.92% | +37.30% | $1.3M | +5.39% | 16b | Stalk |
| Feb 23, 2024 | Buy | DGX | Catherine T. Doherty | EVP, Regional Businesses | 13,071 | $125.02 | $25.9B | -4.92% | +37.30% | $1.6M | +3.68% | 16b | Stalk |
| Feb 23, 2024 | Buy | DGX | J. E. Davis | CEO and President | 19,915 | $125.02 | $25.9B | -4.92% | +37.30% | $2.5M | +2.62% | 16b | Stalk |
| Feb 21, 2024 | Sell | DGX | Michael J Deppe | SVP, Corp. Controller & CAO | 89 | $125.02 | $25.9B | -4.92% | +37.30% | $11.1K | -0.26% | — | Stalk |
| Feb 21, 2024 | Sell | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 102 | $125.02 | $25.9B | -4.92% | +37.30% | $12.8K | -0.72% | — | Stalk |
| Feb 21, 2024 | Sell | DGX | Patrick Plewman | SVP for Diagnostic Services | 139 | $125.02 | $25.9B | -4.92% | +37.30% | $17.4K | -0.92% | — | Stalk |
| Feb 21, 2024 | Sell | DGX | J. E. Davis | CEO and President | 762 | $125.02 | $25.9B | -4.92% | +37.30% | $95.3K | -0.61% | — | Stalk |
| Feb 21, 2024 | Sell | DGX | Michael E Prevoznik | SVP & General Counsel | 1,068 | $125.71 | $25.9B | -4.92% | +37.30% | $134.3K | -1.30% | 10b5-1 | Stalk |
| Feb 21, 2024 | Sell | DGX | Catherine T. Doherty | EVP, Regional Businesses | 1,314 | $125.72 | $25.9B | -4.92% | +37.30% | $165.2K | -0.91% | 10b5-1 | Stalk |
| Jan 31, 2024 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 17 | $129.33 | $25.9B | -4.92% | +37.30% | $2.2K | +0.10% | — | Stalk |
| Jan 31, 2024 | Buy | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 29 | $129.33 | $25.9B | -4.92% | +37.30% | $3.8K | +0.25% | — | Stalk |
| Jan 31, 2024 | Buy | DGX | Patrick Plewman | SVP for Diagnostic Services | 50 | $129.33 | $25.9B | -4.92% | +37.30% | $6.5K | +0.40% | — | Stalk |
| Oct 23, 2023 | Buy | DGX | Sam Samad | Executive Vice President & CFO | 18 | $122.86 | $25.9B | -4.92% | +37.30% | $2.2K | +0.11% | — | Stalk |
| Oct 23, 2023 | Buy | DGX | Karthik Kuppusamy | SVP, Clinical Solutions | 30 | $122.86 | $25.9B | -4.92% | +37.30% | $3.7K | +0.26% | — | Stalk |
| Oct 23, 2023 | Buy | DGX | Patrick Plewman | SVP for Diagnostic Services | 52 | $122.84 | $25.9B | -4.92% | +37.30% | $6.4K | +0.42% | — | Stalk |
| Sep 25, 2023 | Sell | DGX | Mark A Gardner | SVP of Molecular Gen & Oncol | 116 | $126.22 | $25.9B | -4.92% | +37.30% | $14.6K | -3.97% | — | Stalk |